Vaxess Technologies today announced a rebranding to Terrestrial Bio, Inc., along with $50 million in Series C financing.

In this interview, Dr. John Bishop discusses the scientific and regulatory challenges of NAM adoption, where companies should ...

Alongside the rebrand, Terrestrial is planning to establish a new headquarters and manufacturing facility in Boston.

This year’s most innovative smaller companies prove that head count doesn’t cap ambition. These Small and Mighty standouts (51 to 200 employees) are thinking well beyond their ...

Micron Biomedical, a clinical stage company developing dissolvable, needle-free products that could replace injectable pharmaceuticals and vaccines, today announced it was named to the number two spot ...

Get our Editor-in-Chief Michelle Itano's BioTechniques Q1 2026 highlights, featuring an optimized Southern blot protocol and ...

Genomics improves healthcare and prevention of all major diseases by early personalized insight into health, and Europe needs ...

A strategic partnership between Vaxxas and Profenso, an Australian AI company specialising in advanced automation for ...

A bargain DNA kit ordered on a whim seemed like harmless fun for one British woman, until the results unsettled her family's ...

Understanding gene expression within the body has been a boon for 21st century biology and therapeutics, but most discoveries ...

The global digital dentistry market is growing steadily, expected to be valued at around US$ 7.2 billion in 2026 and ...

Botstein, Princeton’s Anthony B. Evnin ‘62 Professor of Genomics, Emeritus, and an emeritus professor of molecular biology ...